Background Cartilage-hair hypoplasia (CHH) is an autosomal recessive chondrodysplasia caused by RMRP (RNA component of mitochondrial RNA processing endoribonuclease) gene mutations. Manifestations include short stature, variable immunodeficiency, anaemia and increased risk of malignancies, all of which have been described also in telomere biology disorders. RMRP interacts with the telomerase RT (TERT) subunit, but the influence of RMRP mutations on telomere length is unknown. We measured relative telomere length (RTL) in patients with CHH, their first-degree relatives and healthy controls and correlated RTL with clinical and laboratory features. Methods The study cohort included 48 patients with CHH with homozygous (n=36) or compound heterozygous RMRP mutations (median age 38.2 years, range 6.0-70.8 years), 86 relatives (74 with a heterozygous RMRP mutation) and 94 unrelated healthy controls. We extracted DNA from peripheral blood, sequenced the RMRP gene and measured RTL by qPCR. Results Compared with age-matched and sex-matched healthy controls, median RTL was significantly shorter in patients with CHH (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10, p=0.224). RTL correlated significantly with age in RMRP mutation carriers (r=−0.482, p<0.001) and non-carriers (r=−0.498, p<0.001), but not in patients (r=−0.236, p=0.107). In particular children (<18 years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008). In patients with CHH, RTL showed no correlation with genotype, clinical or laboratory characteristics. Conclusions Telomere length was decreased in children with CHH. We found no correlation between RTL and clinical or laboratory parameters.
INTRODUCTION
Telomeres constitute the protective end parts of human chromosomes and can contribute to the pathogenesis of ageing and cancer. The phenotype of inherited telomere disorders includes bone marrow failure, malignancies, pulmonary fibrosis, liver cirrhosis, diabetes and cardiovascular and gastrointestinal diseases. 1 Telomeres shorten with every cell division, but the loss can be compensated by telomerase-mediated elongation. The telomerase ribonucleoprotein complex consists of an RNA template, a catalytic RT subunit (telomerase RT (TERT)) and associated proteins that affect assembly, stability and recruitment of telomerase to telomeres (eg, DKC, NOP10, NHP2 and GAR).
In addition to telomere elongation, telomerase has also been associated with regulation of a number of cellular functions, including survival, inflammation, apoptosis, transcription and metabolism. 2 Cartilage-hair hypoplasia (CHH, MIM #250250) is a rare autosomal recessive metaphyseal chondrodysplasia caused by biallelic mutations in the RMRP (RNA component of mitochondrial RNA processing endoribonuclease) gene. 3 The disease is over-represented in the Amish and Finnish populations. 4 5 Clinical features include severe disproportionate short stature, hair hypoplasia, variable immunodeficiency, anaemia and increased risk of malignancies. Genotype-phenotype correlations are inconsistent and clinical manifestations vary even between siblings. 6 Mutation carriers remain asymptomatic. 5 7 Complex pathogenesis of CHH involves cell cycle impairment and altered regulation of genes associated with cell proliferation and differentiation. 8 9 In addition, the formation of a ribonucleoprotein complex by RMRP and TERT has been confirmed. 10 This complex produces doublestranded RNAs and regulates RMRP expression.
Disorders of telomere maintenance, such as dyskeratosis congenita (DC), share some clinical features with CHH, for example, growth retardation, bone marrow failure leading to anaemia and immunodeficiency and increased incidence of malignancies. 11 Pulmonary fibrosis has also been linked to TERT mutations, both in idiopathic cases and in patients with DC. 12 Interestingly, we have recently reported fibrosis-like changes on highresolution CT of the lungs in some patients with CHH. 13 Despite the known association between RMRP and TERT, it remains unknown whether RMRP mutations have a significant impact on the telomere-elongating functions of telomerase. In order to further elucidate the pleiotropic consequences of RMRP mutations and the pathogenesis of CHH, we evaluated relative telomere lengths (RTLs) in a large cohort of Finnish children and adults with CHH; their first-degree relatives, most of whom were heterozygous mutation carriers and healthy controls. We also analysed the correlation of RTL with the patients' clinical and laboratory features.
METHODS
Patients with genetically confirmed CHH were identified from the Finnish Chondrodysplasia Register and recruited to a study exploring clinical, genetic and immunological characteristics of CHH. Their firstdegree relatives were contacted via the index persons. All individuals who agreed to participate, or their guardians, signed an informed consent.
Clinical and laboratory data were retrieved retrospectively from the patient hospital records, as well as prospectively during study visits. Apart from CHH-related clinical features, we also evaluated factors that could theoretically influence telomere length, such as smoking, obesity (body mass index Z-score) and hormone or immunosuppressive therapy. We also selected clinical features that could emerge from telomere impairment (immunodeficiency, malignancies, short stature), as well as the need for repeated blood transfusions and immunoglobulin replacement therapy. Since growth failure in CHH is progressive, we used age-specific and sex-specific growth data for CHH 14 to classify patients as having mild, moderate or severe growth failure, as described previously. 15 In the majority of patients, blood samples were drawn simultaneously for telomere measurement and for analysis of immunological parameters characterising the degree of bone marrow deficiency and/or immunodeficiency: haemoglobin; red blood cells; leucocytes; neutrophils; lymphocytes; CD3+, CD4+, CD8+, CD19 + and CD16/56+ cell counts; IgA, IgM and IgG levels, as well as Epstein-Barr virus (EBV) viral load and antibodies.
Control group
First-degree relatives of the patients (n=86), all without features of CHH, included 37 parents, 38 siblings and 11 children. Altogether, 74 of them were confirmed to be heterozygous RMRP mutation carriers, while 12 were negative for RMRP mutations. The control group consisted of RMRP mutationnegative individuals: (1) siblings of the patients (n=12) and (2) individuals who had participated in our previous studies involving healthy children and adults (n=94). The data available on controls included age, sex, ethnic background (all of Finnish origin) and overall health (all healthy). Parts of the statistical analyses were performed in a case-control setting, and agematched and sex-matched controls were selected from the control group for each patient or mutation carrier aiming at age difference of no more than 12 months.
DNA extraction and RMRP sequencing
Peripheral blood samples were collected for all study participants. DNA was extracted with five Prime Archive Pure DNA Blood Kit according to manufacturer's instructions (5 Prime GmbH, Hilden, Germany). All samples were sequenced for RMRP to confirm the genotype in patients with CHH and to confirm or exclude heterozygous mutations in the patients' unaffected relatives and the healthy controls. For patients and their relatives, blood samples were collected prospectively, whereas readily available DNA (extracted with the same methods) was used for healthy controls. Primers for RMRP (GRCh37/hg19) were designed with Primer3 V.0.4.0 (http:// frodo.wi.mit.edu/primer3/) for the gene, with a minimum of 60 bases of flanking regions adjacent to the coding region. PCR amplification was performed with DreamTaq (ThermoScientific, Waltham, Massachusetts, USA). The DNA fragments were then visualised with Midon Green Advanced DNA Stain (NIPPON Genetics Europe GmbH, Dueren, Germany) on a 1.2% agarose gel, purified with ExoSAP (USB, Cleveland, Ohio, USA) and labelled with BigDye Terminator V.3.1 Cycle Sequencing Kit (Applied Biosystems). After bidirectional sequencing with an ABI 3730 Sequencer (Applied Biosystems), chromatograms were analysed with Sequencher V.5.0 (Gene Codes, Ann Arbor, Michigan, USA) using genomic NG_017041.1 and RNA reference sequence NR_003051.3. Primer sequences and detailed PCR protocols are available upon request.
Telomere length measurement
Telomere length was determined by the qPCR method described by Cawthon, 16 with minor modifications. 17 Briefly, sample DNA was analysed in triplicate wells in a separate Telomere (TEL) and a single-copy gene human beta-hemoglobin (HBG) reaction on the ABI 7900HT Instrument (Applied Biosystems) at two separate times. TEL/HBG (T/S) values were calculated by the 2 −ΔCt method, where ΔCt=average Ct TEL -average Ct HBG . RTLs were generated by dividing sample T/S values with the T/ S value of a reference CCRF-CEM cell line DNA included in all runs.
Statistical analysis
Subject's age on the day of blood sampling was used for the analyses. To evaluate RTL correlations, we classified individuals into categories of short, average or long RTL for age and used both, RTL itself and RTL category, in the analysis. These categories were determined based on RTL and age data from the healthy controls. Individuals with RTL >0.5 SD from the regression line for age versus RTL were classified as having long RTL, those with RTL <−0.5 SD as having short RTL and the remaining as having average RTL (see online supplementary figure S1). We applied the Mann-Whitney test for categorical variables and the Spearman's correlation coefficient (r) for continuous variables. Linear or logistic regression analysis was used for multivariate models. A p value <0.05 was considered significant. Statistical analyses were performed with the IBM SPSS software.
RESULTS

Patient characteristics
Altogether, 48 Finnish patients (31 women, 17 men) with CHH participated in the study. Their median age was 38.2 years (range 6.0-70.8 years). Sanger sequencing of the RMRP gene showed that most of the patients (75%, 36/48) were homozygous for the g.70A>G mutation (rs199476103, now referred to as g.71A>G), while 12 patients (25%) were compound heterozygous for g.70A>G and either a g.262G>T mutation (rs727502774, now referred to as g.263G>T) (n=11) or a 10-nucleotide duplication at position-13 (TACTCTGTGA, rs727502775) (n=1). Tables 1 and 2 present patients' clinical and laboratory data. Nine patients had been diagnosed with malignancies, including basal cell carcinoma (n=6), B-cell lymphoma (n=2), uterus carcinoma (n=1) and vocal cord carcinoma (n=1). In the two patients who had survived lymphoma, no data were available on EBV status in lymphoma samples. No EBV-associated diseases were reported in our patients. Blood EBV viral load was undetectable by PCR in 10 individuals and 34/41 (83%) patients tested positive for serum antibodies to EBV. Two patients had required repeated red blood cell transfusions for anaemia and another four patients had been treated with immunoglobulin replacement therapy. Some individuals reported history of smoking (n=9), use of inhaled corticosteroids for physiciandiagnosed asthma (n=15) or growth hormone treatment in childhood (n=3).
Telomere length RTL measurement was performed by qPCR on altogether 228 samples from patients (n=48), first-degree relatives (n=86) and healthy unrelated controls (n=94). Sanger sequencing detected 74 carriers for RMRP mutations among the unaffected relatives of patients with CHH (86%). Table 3 demonstrates the characteristics of the participants according to the RMRP mutation status. There was a significant negative correlation between RTL and age in mutation carriers (r=−0.482, p<0.001) and non-carriers (r=−0.498, p<0.001), but not in patients (r= −0.236, p=0.107) (figure 1). RTL was not influenced by sex in any age group.
RTL in patients and mutation carriers
The proportion of patients with CHH with short RTL for age was significantly higher (52%, 25/48) than among mutation carriers (20%, 15/74, p<0.001) or healthy non-carriers (29%, 31/ 106, p=0.011) (table 4). In the subanalysis by age group, almost all children with CHH had short telomeres for age (89%, 8/9 ). Further, two-thirds of patients aged 18.1-40.0 years (65%, 11/ 17) and one-fourth of those aged over 40.1 years (27%, 6/22) had short telomeres. Compared with RMRP mutation-negative individuals, the proportion of patients with short RTL was significantly higher in children (p=0.016) and adults up to 40.0 years of age ( p=0.047), but not in older individuals (p=0.769) (table 4).
We were able to find from the control group age-matched and sex-matched controls with no RMRP mutations for 40 patients (12 men, 28 women, median age 37.5 years) for case-control analyses. RTL was significantly shorter in patients (median RTL 1.05) compared with controls (median RTL 1.21, p=0.017). Children aged ≤18 years accounted for this difference in RTL (median 1.09 in patients vs 1.25 in controls, p=0.015, n=8 pairs), while only a trend for shorter RTL was observed in those aged >18 and ≤40 years (median 1.07 vs 1.26 in controls, p=0.069, n=14 pairs) and no difference was detected in the age group >40 years (median RTL 1.03 vs 1.08 in controls, p=0.443, n=18 pairs) (figure 2).
When all study samples were included in analyses, a significant difference in RTL between patients with CHH and healthy subjects (including RMRP mutation carriers and non-carriers) was also observed in children (6.0-18.0 years of age, median RTL 1.12 in 9 patients vs 1.26 in 36 controls, p=0.008) (figure 3). No significant difference was detected in the older age groups, although young adults with CHH demonstrated a tendency for shorter telomeres (median RTL 1.08 in 17 patients vs 1.22 in 52 controls, p=0.082).
We compared RTL in 48 RMRP mutation carriers with agematched and sex-matched non-carrier controls and observed no difference in the median RTL between these two groups (1.16 vs 1.10, p=0.224) (data not shown). 
RTL-related and CHH-related characteristics and morbidity
In the patient cohort, RTL and classified RTL (short, average or long for age) showed no correlation with the type of RMRP mutation, sex, history of blood transfusions, immunoglobulin substitution, hormone or immunosuppressive therapy, obesity or history of smoking. Various infectious manifestations separately or in combinations, fibrosis-like lung changes, history of malignancies, the severity of growth failure and analysed laboratory parameters did not correlate with RTL itself or RTL category (see online supplementary table S1). In two patients who had survived lymphoma, RTL was average and long for age, respectively.
DISCUSSION
Our study demonstrates shorter telomeres in DNA from peripheral blood in children with CHH. The interpretation of our findings necessitates further studies to determine whether shorter telomeres are the cause or the consequence in CHH pathology. Decreased telomere length may reflect the increased number of cell divisions required to compensate for the impaired cell cycle and increased apoptosis reported in CHH. 18 Alternatively, telomerase defects can represent primary RTL was significantly shorter in children with CHH (median 1.09 vs 1.25 in controls, p=0.015, n=8 pairs). Adults with CHH showed a trend for shorter RTL in the age group >18 and ≤40 years (median 1.07 vs 1.26 in controls, p=0.069, n=14 pairs), while no difference was detected in the age group >40 years (median RTL 1.03 vs 1.08 in controls, p=0.443, n=18 pairs). o, outliers; *, extreme outlier. *Other mutations included g.262G>T or a 10-nucleotide duplication at position-13 (TACTCTGTGA). CHH, cartilage-hair hypoplasia; F, female; M, male; n, number of subjects; n/a, not applicable; RMRP, RNA component of mitochondrial RNA processing endoribonuclease.
pathological mechanism contributing to stem cell exhaustion, including bone marrow failure present in some patients with CHH. Our findings confirm the significance of RMRP in telomerase function. RTL correlated significantly with age in RMRP mutation carriers and non-carriers, but not in patients with CHH, which can be explained by shorter telomeres in paediatric patients. Individuals with CHH have increased mortality in childhood and young adulthood from infections and malignancies. 19 20 A high proportion of our patients (46%, 22/48) were over 40 years of age and thus represent a selected population of less affected patients who escaped fatal complications in early life. Therefore, normal telomere length in adults with CHH can indicate a survival advantage. The absence of correlations between telomere length and clinical and laboratory characteristics can derive from the small sample size. Also, RTL is a rough estimate of telomere structure and represents only a part of the complex telomere biology.
Interestingly, some DC mutation carriers demonstrate telomere shortening while remaining asymptomatic and inheritance of shorter telomeres probably induces more severe disease in subsequent generations. 21 The finding of normal telomeres in RMRP mutation carriers contradicts the data from families with DC. More research is needed to test pedigrees where CHH has been diagnosed in more than one generation. If the shorter telomere length is indeed inherited, this may result in more severe disease in the affected offspring of patients with CHH in future generations.
Cell immortalisation and subsequent development of cancer can emerge from abnormal telomere maintenance. 22 While DC and CHH are both characterised by increased risk of malignancies, the types of tumours developing in patients with these disorders differ. The most common malignancies in individuals with DC include head and neck squamous cell carcinomas, while in subjects with CHH, non-Hodgkin's lymphomas and basal cell carcinomas predominate. 20 23 Accordingly, in the light of present data, immunodeficiency rather than the telomere length is the nominator in predisposition to malignancy in patients with CHH. Immunodeficiency in patients with CHH may predispose them to EBV-associated lymphoproliferative disorders. Unfortunately, no data were available on EBV status in lymphoma samples from the two patients in our cohort. The majority of our patients had detectable serum antibodies to EBV but EBV DNA was not detected by PCR in peripheral blood. EBV causes telomere dysfunction in the infected cells 24 25 and it is possible that this is relevant in CHH. Therefore, further research on alteration in telomere functions and the role of EBV in patients with CHH with malignancies would be warranted.
The results of our study have important clinical implications. Patients with CHH can require haematopoietic stem cell transplantation and defective telomere biology should be taken into account when choosing conditioning regimen. Also, bone marrow failure in patients with DC has been successfully treated with androgens ( probably due to telomerase upregulation) and this treatment option may be considered in selected patients with CHH. [26] [27] [28] Furthermore, telomere length measurement may guide diagnostic process in individuals with immunodeficiency of unknown aetiology and CHH should be included in the differential diagnosis of children with short telomeres.
We recognise strengths and limitations in our study. This is the first study to evaluate telomere length in patients with CHH. The high prevalence of the disease in our population provided us with a unique opportunity to recruit a large cohort of patients and their unaffected relatives with a homogenous genetic and ethnic background and with a wide age range; in rare diseases such an approach is seldom possible. The drawbacks of our study include insufficient clinical data from relatives of patients with CHH and healthy controls. Thus, it was impossible to analyse the influence of, for example, smoking or medications on RTL. However, in the patient group, these factors did not affect telomere length and none of the patients aged <18 years reported smoking. The number of healthy controls was rather small, which increases the risk of bias and due to the interindividual variability of telomere length, our data may not be applicable to particular individuals with CHH. Also, no data were available on metabolic profile (glucose, insulin and lipid profile, blood pressure) of our patients, hindering the evaluation of its relationship with RTL. Another limitation is the use of RTL, where mean telomere length of all chromosome ends is estimated. Telomere length distributions and critically short individual telomere ends cannot be detected by this method.
Our results suggest that telomere length is abnormal in children with CHH. Further studies are required to explore functional consequences of altered telomere maintenance and possible clinical implications of these findings. Longitudinal follow-up of patients with CHH is necessary to establish the significance of telomere length as a predictor of disease severity and mortality.
